Capricor Therapeutics (CAPR) Downgraded by Zacks Investment Research to Hold

Capricor Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Capricor Therapeutics Downgraded by Zacks Investment Research on 10/13/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of Capricor Therapeutics traded up $0.14 on Wednesday, reaching $4.12. 161849 shares of the stock traded hands, compared to its average volume of 1259731. Shares of Capricor Therapeutics were trading at $4.12 on Wednesday. The firm’s 50 day moving average is $4.37 and its 200 day moving average is $4.78.Capricor Therapeutics has a 12 month low of $3.97 and a 12 month high of $8.40. While on yearly highs and lows, Capricor Therapeutics’s today has traded high as $4.16 and has touched $3.97 on the downward trend. See More Analyst Rating at: RATING

Capricor Therapeutics Earnings and What to expect: 

Capricor Therapeutics last posted its earnings results on August 12th, 2021. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. The company had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.21 million. Capricor Therapeutics has generated ($0.88) earnings per share over the last year (($0.85) diluted earnings per share). Earnings for Capricor Therapeutics are expected to decrease in the coming year, from ($0.90) to ($0.95) per share. Capricor Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for Capricor Therapeutics are expected to decrease in the coming year, from ($0.90) to ($0.95) per share. The P/E ratio of Capricor Therapeutics is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Capricor Therapeutics is -4.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Capricor Therapeutics has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Capricor Therapeutics (CAPR) Moving Average Technical Analysis

5 day Moving Average is $3.92 And 5 day price change is $0.44 (11.96%)  with average volume for 5 day average is 240,620. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $4.29 and 20 day price change is -$0.33 (-7.42%) and average 20 day moving volume is 1,773,585. 50 day moving average is $4.37  and 50 day price change is -$0.33 ( -7.42%)  and with average volume for 50 days is : 821,270. 200 day moving average is $4.78  and 200 day price change is $0.08 (1.98%)  and with average volume for 200 days is : 709,032.

Other owners latest trading in Capricor Therapeutics :

  • On 8/23/2021 shares held by Morgan Stanley were 44,450 which equates to market value of $0.23M and appx 0.00% owners of Capricor Therapeutics
  • On 8/17/2021 shares held by Millennium Management LLC were 13,544 which equates to market value of $69K and appx 0.00% owners of Capricor Therapeutics
  • On 8/17/2021 shares held by Oracle Investment Management Inc. were 1,166,249 which equates to market value of $5.98M and appx 0.80% owners of Capricor Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 15.31% for Capricor Therapeutics

See More Analyst Rating at: RATING